CELFULL Women‘s NADH Formula
Natural health product licensed in Canada
If this product were sold in France
- Conditions légales
Linum usitatissimum L.: L'étiquetage doit comporter un avertissement déconseillant l'usage chez les femmes ayant des antécédents personnels ou familiaux de cancer du sein.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Acide 1H-pyrrolo(2,3-f)quinoline-2,7,9-tricarboxylique, 4,5-dihydro-4,5-dioxo- Source : Pyrroloquinoline quinone disodium salt | 10 mg | Not calculated |
| Linum usitatissimum Source : Linum usitatissimum - Graine | 100 mg | Not calculated |
| Dinucléotide de 1,4-dihydronicotinamide adénine | 10 mg | Not calculated |
| Chamaemelum nobile Extract : Matériel brut sec Extraction ratio : 10:1 Dry plant equivalent : 900 mg | 90 mg | Not calculated |
| Ceratonia siliqua Extract : Matériel brut sec Extraction ratio : 40:1 Dry plant equivalent : 6,000 mg | 150 mg | Not calculated |
| Folate Source : Acide folique | 0.45 mg | Not calculated |
Non-medicinal ingredients
Dioxyde de silicium, Hypromellose, Palmitate de magnésium, Cellulose microcristalline, Stéarate de magnésium
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | minimum: 18 years | 1 Capsule | 2 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
Helps to form red blood cells. Helps to maintain/support the body's ability to metabolize nutrients. Source of (an) antioxidant(s)/Provides (an) antioxidant(s) that help(s) fight/protect (cell) against/reduce (the oxidative effect of/the oxidative damage caused by/cell damage caused by) free radicals. Source of (an) antioxidant(s)/Provides (an) antioxidant(s). Helps to increase energy production (ATP) at the cellular level. Helps support Mitochondrial function.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Product record
- Other names
- CELFULL NADH Complex
- Licence holder
- CELFULL BIO-TECH (USA) INC.
- NPN or DIN-HM
- 80133807
- Status
- Active licence
- Licence date
- 26 August 2024
- Revision date
- 18 August 2026
- Form
- Capsule, dur
- Route of administration
- Orale
- Application type
- Générale (non traditionelle)
Source
Official Health Canada record, licence 80133807
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Linum usitatissimum
Read the warning, when it applies and the studies cited
FLAXSEED - LINUM USITATISSIMUM
Route of administration: Oral
Cautions and warnings
Applies to products providing 5 g or more of flaxseed per day.
Ask a health care practitioner/health care provider/health care professional/doctor/physician immediately if you experience chest pain, vomiting, or difficulty swallowing or breathing after taking this product (EMA 2015).
Sources cited by Health Canada (1)
- EMA 2015. European Medicines Agency. European Union Herbal Monograph on Linum usitatissimum L., semen. London (GB): EMA Committee on Herbal Medicinal Products (HMPC), 10 March 2015. [Accessed 2023 December 31]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-linum-usitatissimum-l-semen_en.pdf
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have diabetes or a lazy bowel (EMA 2015; ESCOP 2003).
Sources cited by Health Canada (2)
- EMA 2015. European Medicines Agency. European Union Herbal Monograph on Linum usitatissimum L., semen. London (GB): EMA Committee on Herbal Medicinal Products (HMPC), 10 March 2015. [Accessed 2023 December 31]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-linum-usitatissimum-l-semen_en.pdf
- ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme.
Condition of application: Laxative; Promotion of bowel movement; Constipation.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen or if laxative effect does not occur within 7 days (Pray 2006; Repchinsky 2002).
Sources cited by Health Canada (2)
- Pray WS. 2006. Non-Prescription Product Therapeutics, 2nd edition. New York (NY): Lippincott Williams & Wilkins.
- Repchinsky 2002: Canadian Pharmacists Association. Patient Self-Care. Helping Patients Make Therapeutic Choices. Ottawa (ON): Canadian Pharmacists Association.
Contraindications
Applies to products providing 5 g or more of flaxseed per day.
Do not use if you have difficulty swallowing (EMA 2015; ESCOP 2003).
Sources cited by Health Canada (2)
- EMA 2015. European Medicines Agency. European Union Herbal Monograph on Linum usitatissimum L., semen. London (GB): EMA Committee on Herbal Medicinal Products (HMPC), 10 March 2015. [Accessed 2023 December 31]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-linum-usitatissimum-l-semen_en.pdf
- ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme.
Do not use if you have fever or any undiagnosed gastrointestinal trouble (EMA 2015; Gardner and McGuffin 2013; Brinker 2010; ESCOP 2003).
Sources cited by Health Canada (4)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- EMA 2015. European Medicines Agency. European Union Herbal Monograph on Linum usitatissimum L., semen. London (GB): EMA Committee on Herbal Medicinal Products (HMPC), 10 March 2015. [Accessed 2023 December 31]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-linum-usitatissimum-l-semen_en.pdf
- ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme.
- Gardner Z. and McGuffin M. editors. American Herbal Products Association's Botanical Safety Handbook, 2nd edition. American Herbal Products Association. Boca Raton (FL): CRC Press; 2013.
Known adverse reactions
Condition of application: All products.
Stop use if hypersensitivity/allergy occurs (EMA 2015; León et al. 2003).
Sources cited by Health Canada (2)
- EMA 2015. European Medicines Agency. European Union Herbal Monograph on Linum usitatissimum L., semen. London (GB): EMA Committee on Herbal Medicinal Products (HMPC), 10 March 2015. [Accessed 2023 December 31]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-linum-usitatissimum-l-semen_en.pdf
- León F, Rodríguez M, Cuevas M. 2003. Anaphylaxis to Linum. Allergologia et immunopathologia 31(1):47-49.
- Chamaemelum nobile
Read the warning, when it applies and the studies cited
Roman Chamomile - Chamaemelum Nobile
Route of administration: Oral (Wichtl 2004; Bradley 1992)
Cautions and warnings
Ask a healthcare practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Known adverse reactions
Stop use if hypersensitivity/allergy occurs (Brinker 2010; Mills and Bone 2000; Blumenthal et al. 1998).
Sources cited by Health Canada (3)
- Blumenthal M, Busse WR, Goldberg A, Gruenwald J, Hall T, Riggins CW, Rister RS, editors. Herbal Medicine: Complete Commission E Monographs. Boston (MA): Integrative Medicine Communications; 1998.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Mills S, Bone K. Principles and Practice of Phytotherapy. Toronto (ON): Churchill Livingstone; 2000.
They concern the ingredient, not this product or its dose. They do not replace medical advice.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
Has the product changed? Photograph the packaging.
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “CELFULL Women‘s NADH Formula”, https://compoatlas.com/en/supplements/canada/80133807-celfull-women-s-nadh-formula, updated 18 August 2026.